OTLC OTLC

Oncotelic Therapeutics (QB) Stock Price

0.191
-0.036 (-15.86%)
0.191
Volume 449,626
Bid Price 0.1701
Ask Price 0.21
News -
Day High 0.228

Low
0.0805

52 Week Range

High
0.34

Day Low 0.17
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncotelic Therapeutics Inc (QB) OTLC OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.036 -15.86% 0.191 16:01:15
Open Price Low Price High Price Close Price Prev Close
0.227 0.17 0.228 0.227
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
84 449,626 $ 0.19013 $ 85,487 - 0.0805 - 0.34
Last Trade Time Type Quantity Stock Price Currency
15:58:01 1,000 $ 0.191 USD

Period:

Draw Mode:

Oncotelic Therapeutics Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 72.12M 377.61M 170.97M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
8.61k $ - - - -

more financials information »

Oncotelic Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OTLC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.230.230.15030.2080599123,080-0.039-16.96%
1 Month0.22950.2350.15030.2204105108,792-0.0385-16.78%
3 Months0.2350.2590.15030.23111114,445-0.044-18.72%
6 Months0.1180.2590.08050.180661187,6940.07361.86%
1 Year0.2810.340.08050.1689014189,693-0.09-32.03%
3 Years0.240.360.08050.1863116194,505-0.049-20.42%
5 Years0.240.360.08050.1863116194,505-0.049-20.42%

Oncotelic Therapeutics (QB) Description

Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin) and VDA agents (Oxi4503/CA4P) against viral infections and various tumors including three rare pediatric tumors (DIPG, Melanoma, and AML). The program is being funded by our partner GMP through a JV that we are intend to take IPO. 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas).


Your Recent History
USOTC
OTLC
Oncotelic ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.